-+ 0.00%
-+ 0.00%
-+ 0.00%

ZIIHERA® (ZANIDATAMAB-HRII) COMBINATIONS ACHIEVE UNPRECEDENTED RESULTS IN FIRST-LINE HER2+ LOCALLY ADVANCED OR METASTATIC GEA INCLUDING MORE THAN TWO YEARS MEDIAN OVERALL SURVIVAL BENEFIT

Reuters·01/06/2026 18:32:58

Please log in to view news